The pharmaceutical and biological industry is navigating a new era of complexity. Driven by rapid scientific advancements, drug development is no longer limited to small molecules. Today, researchers are tackling everything from biologics and complex dosage forms to intricate drug combinations. This shift has created an unprecedented need for specialized expertise and vast resources. Additionally, developing and validating methods for drug molecules that require detection at very low concentrations adds another layer of difficulty, especially when complex matrices or interference from endogenous compounds are involved. Coordinating with multiple vendors across different drug development stages creates communication gaps and higher risks causing costs rise quickly, timelines often stretch longer than anticipated, and even minor setbacks can derail years of investment. Overcoming these challenges requires advanced instrumentation, technical precision, and a partner capable of managing every process under one roof while meeting global standards. As the first and largest pharmacokinetics and global central lab Contract Research Organization (CRO) in Indonesia and Southeast Asia, Equilab International has emerged as a trusted partner in this space and provides end-to-end service for many Sponsors. They provide seamless solution from designing the study to regulatory study approval until the development of clinical study report. The company has completed more than 1,500 studies for 400 global clients and remains a leading choice for organizations seeking a comprehensive service provider in Asia. At the core of Equilab International’s strength is its central laboratory. The company has validated over 300 molecules across a wide range of therapeutic areas, giving the sponsors confidence that even highly complex compounds can be analyzed with precision and very low detection limit. Methods are kept current with evolving regulations through regular revalidation. Ongoing equipment maintenance and continuous staff training further ensure precision and reliability in every analysis. Furthermore, as a central lab, we also have the experience to analyse the pharmacokinetic samples coming from other countries such as the Philippines and Nepal..

In the race to develop safer, smarter, and more sustainable health solutions, one company has redefined what’s possible with chitosan. BIO21, operating from a GMP, HACCP, FDA-approved, EU-certified facility in Indonesia in partnership with PT. Fresh On Time Seafood, controls every stage from ocean harvest to molecular-level formulation. This rare vertical integration, combined with advanced R&D expertise, has made the company a trusted partner for life science innovators across Europe, North America, and Japan. Founded in 2005 and headquartered in Thailand, BIO21’s vertically integrated model is its greatest strength. From harvesting snow crab shells in deep-sea, low-pollution environments to delivering medical-grade chitosan, BIO21 controls every stage of the journey. Few suppliers can match its commitment to double raw material checks—first for seafood fit for human consumption, then again for suitability as a pharmaceutical-grade biopolymer. The company’s approach ensures every batch meets the highest safety and purity standards. But BIO21’s competitive edge goes far beyond compliance. Its research and development team specializes in engineering chitosan at the molecular level. Critical parameters such as degree of deacetylation, molecular weight, viscosity, and chitosan type (alpha or beta) are precisely tailored to meet the functional, clinical, and regulatory needs of each client. The capacity for fine-tuning is not common in the industry, and it has made BIO21 a trusted partner for high-stakes applications. One example of BIO21’s problem-solving ability can be seen in its work with a medical device company developing a next-generation hemostatic dressing. The client needed biodegradable polymer materials that could pass rigorous EU and FDA standards. BIO21 responded with a custom formulation, carefully optimizing molecular weight, viscosity, and purity to meet exact specifications. Beyond supplying the material, the company actively supported the testing process and helped streamline regulatory documentation, leading to faster approval and a smoother product launch. Treating Sustainability as a Core Design Principle The company’s innovation pipeline is equally notable in the nutraceutical space. Its L112 Biopolymer, developed through close R&D collaboration, is designed to support cardiovascular health and fat reduction. Projects like this show how BIO21 transforms raw scientific expertise into real-world, market-ready performance..